Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 9, 2013, Pages 799-807

  Reiner, Z ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Cardiovascular diseases; Fibrates; Hypertriglyceridaemia; Nicotinic acid; Statins; Triglycerides

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 11; D 4F; DALCETRAPIB; EVACETRAPIB; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; MONOCLONAL ANTIBODY; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DRUG DOSE TITRATION; DYSLIPIDEMIA; HUMAN; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ACCORD; ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES; AIM-HIGH; ARBITER; ARTERIAL BIOLOGY FOR THE INVESTIGATION OF THE TREATMENT EFFECTS OF REDUCING CHOLESTEROL; ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES AND IMPACT ON GLOBAL HEALTH OUTCOMES; BEZAFIBRATE INFARCTION PREVENTION; BIP; CARDIOVASCULAR DISEASES; CHOLESTEROL TREATMENT TRIALISTS; CTT; DAL-OUTCOMES; EAS; EFFECT OF RECONSTITUTED HDL ON ATHEROSCLEROSIS-SAFETY AND EFFICACY; ERASE; ESC; EUROPEAN ATHEROSCLEROSIS SOCIETY; EUROPEAN SOCIETY OF CARDIOLOGY; FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES; FIBRATES; FIELD; HEART PROTECTION STUDY 2: TREATMENT OF HDL TO REDUCE THE INCIDENCE OF VASCULAR EVENTS; HPS2-THRIVE; HYPERTRIGLYCERIDAEMIA; ILLUMINATE; INVESTIGATION OF LIPID LEVEL MANAGEMENT TO UNDERSTAND ITS IMPACT IN ATHEROSCLEROTIC EVENTS; NICOTINIC ACID; SCORE; STATINS; STUDY OF THE EFFECT OF DALCETRAPIB ON ATHEROSCLEROTIC DISEASE IN PATIENTS WITH CORONARY ARTERY DISEASE; SYSTEMIC CORONARY RISK ESTIMATION; TRIGLYCERIDES;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; OLIGONUCLEOTIDES; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84884162159     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.05.002     Document Type: Review

References (65)

1. Merkler M., Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol 2007, 21(Suppl. 2):1-3.
2. Reiner Ž. How to improve cardiovascular diseases prevention in Europe?. Nutr Metab Cardiovasc Dis 2009, 19:451-454. 10.1016/j.numecd.2009.06.006.
3. Zannad F., Dallongeville J., Macfadyen R.J., Ruilope L.M., Wilhelmsen L., De Backer G., et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol 2012, 19:1454-1464.
4. Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Boren J., Catapano A.L., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
5. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-113.
6. Reiner Ž., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-7818.
7. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
8. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
9. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
10. Cholesterol Treatment Trialists' Ctt Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 12:60367-60375. 10.1016/S0140-6736.
11. Fruchart J.C., Sacks F., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102(Suppl. 10):1K-34K.
12. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
13. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
14. Perk J., De B.G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012, 33:1635-1701.
15. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012, 380:572-580.
16. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
17. Reiner Ž, Sonicki Z., Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010, 213:598-603. 10.1016/j.atherosclerosis.2010.09.014.
18. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med 2010, 51:494-496. 10.1016/j.ypmed.2010.09.015.
19. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322. 10.1016/j.jacc.2008.10.024.
20. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
21. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31:149-164.
22. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010, 24:19-28.
23. Chen Q., Cheng L.Q., Xiao T.H., Zhang Y.X., Zhu M., Zhang R., et al. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011, 25:259-265.
24. McKenney J.M., Jones P.H., Bays H.E., Knopp R.H., Kashyap M.L., Ruoff G.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007, 192:432-437. 10.1016/j.atherosclerosis.2006.11.037.
25. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361. 10.1016/j.atherosclerosis.2009.12.023.
26. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54:1787-1794. 10.1016/j.jacc.2009.06.036.
27. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
28. Taylor A.J., Lee H.J., Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006, 22:2243-2250.
29. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
30. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
31. Chew E.Y., Ambrosius W.T., Davis M.D., Danis R.P., Gangaputra S., Greven C.M., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
32. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R.I., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
33. The Thrive Study Merck announces HPS2-Thrive study of Tredaptive (extended release Niacin/Laropiprant) did not achieveprimary endpoint [accessed 27.03.13]. http://www.thrivestudy.org/HPS2THRIVE%2520RELEASEUSWIREVERSIONfinal.pdf.
34. European Medicines Agency (EMA) European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn [accessed 25.03.13]. http://www.ema.europa.eu/ema/index.jsp%3fcurl%3dpages/news_and_events/news/2013/01/news_detail_001694.jsp%26mid%3dWC0b01ac058004d5c1.
35. BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
36. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. [Erratum in: Lancet 2006;368:1415].
37. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
38. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
39. Goldenberg I., Benderly M., Goldbourt U. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol 2008, 51:459-465. 10.1016/j.jacc.2007.09.048.
40. Goldenberg I., Boyko V., Tennenbaum A., Tanne D., Behar S., Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 2009, 169:508-514.
41. Scott R., O'Brien R., Fulcher G., Pardy C., D'Emden M., Tse D., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
42. Jun M., Foote C., Lv J., Neal B., Patel A., Nicholls S.J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
43. Tonkin A.M., Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010, 122:850-852.
44. Elam M., Lovato L., Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol 2011, 6:9-20.
45. Sacks F.M., Carey V.J., Fruchart J.C. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-694.
46. Davis T.M., Ting R., Best J.D., Donoghoe M.W., Drury P.L., Sullivan D.R., et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290.
47. Ting R.D., Keech A.C., Drury P.L., Donoghoe M.W., Hedley J., Jenkins A.J., et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012, 35:218-225.
48. Drury P.L., Ting R., Zannino D., Ehnholm C., Flack J., Whiting M., et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011, 54:32-43.
49. Ballantyne C.M., Jones P.H., Kelly M.T., Setze C.M., Lele A., Thakker K.M., et al. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther 2011, 25:59-67.
50. Jones P.H., Cusi K., Davidson M.H., Kelly M.T., Setze C.M., Thakker K., et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010, 10:73-84.
51. Bloomfield D., Carlson G.L., Sapre A., Tribble D., McKenney J.M., Littlejohn T.W., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. AmHeart J 2009, 157:352-360. e2. 10.1016/j.ahj.2008.09.022.
52. Nicholls S.J., Brewer H.B., Kastelein J.J., Krueger K.A., Wang M.D., Shao M., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306:2099-2109.
53. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
54. Di Bartolo B.A., Vanags L.Z., Tan J.T., Bao S., Rye K.A., Barter P.J., et al. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids Health Dis 2011, 10:224.
55. Shaw J.A., Bobik A., Murphy A., Kanellakis P., Blombery P., Mukhamedova N., et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008, 103:1084-1091.
56. Tardif J.C., Grégoire J., L'Allier P.L., Ibrahim R., Lespérance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
57. Bloedon L.T., Dunbar R., Duffy D., Pinell-Salles P., Norris R., DeGroot B.J., et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008, 49:1344-1352.
58. Stein E.A., Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
59. Cuchel M., Meagher E.A., du Toit T.H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
60. Stein E.A., Gipe D., Bergeron J., Gaudet D., Weiss R., Dufour R., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
61. Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006.
62. Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
63. Raal F., Scott R., Somaratne R., Bridges I., Li G., Wasserman S.M., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
64. Sullivan D., Olsson A.G., Scott R., Kim J.B., Xue A., Gebski V., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:1-10.
65. Gumbiner B, Chandrasekhar U, Tenshang, Liang, Wan, Shelton D, etal. The effects of multiple dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin Kexin Type 9, in hypercholesterolemic subjects. American Heart Association Congress 2012 [Abstract No. 13524].